Please ensure Javascript is enabled for purposes of website accessibility

5 Reasons bluebird bio Inc. Took Flight Today

By Brian Orelli, PhD – Jul 27, 2016 at 5:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No direct news for the biotech, but these seem to have added up to a big one-day gain.

Image source: Getty Images.

What: bluebird bio (BLUE 0.93%) ended up 11.2% on no direct news about the company.

So what: While there were no press releases announcing data to be seen, here are a few items that probably contributed to the double-digit gain:

  • A Wells Fargo analyst issued a note pointing to upcoming catalysts, including presentations at the American Society of Hematology (ASH) meeting in December.
  • While ASH isn't until December, abstracts for the meeting will be available on Nov. 3, which isn't too far off.
  • BioMarin Pharmaceuticals presented promising data for its hemophilia gene therapy treatment today. bluebird bio's gene therapy treats other diseases, but given gene therapy's checkered past and Bluebird's struggles, BioMarin's data may be giving investors confidence that Bluebird can fix its expression issues.
  • There have been a couple of recent biotech acquisitions. For example, Laboratory Corporation of America announced today the acquisition of Sequenom for a 182% premium. Investors may be thinking bluebird bio is a potential takeout target, especially at this knocked-down price.
  • It's a biotech; double-digit moves based on the sentiment of day traders are common.

Now what: Bluebird's stock has recovered quite a bit off its lows earlier this year, but to get back to its glory days, investors will need to be convinced that it can consistently produce expression high enough to cure patients with sickle cell disease.

Alternatively, successful data from its CAR-T cancer therapy, bb2121, would increase the company's valuation, although the phase 1 trial was only started recently, so definitive proof-of-concept data will be a while in coming.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical and bluebird bio. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bluebird Bio Stock Quote
Bluebird Bio
$7.59 (0.93%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.